Can prokineticin prevent obesity and insulin resistance?
Fiche publication
Date publication
octobre 2015
Journal
Current opinion in endocrinology, diabetes, and obesity
Auteurs
Membres identifiés du Cancéropôle Est :
Dr NEBIGIL-DESAUBRY Canan
Tous les auteurs :
Von Hunolstein JJ, Nebigil CG
Lien Pubmed
Résumé
Because of its increasing prevalence and morbi-mortality, obesity is a major health problem. Obesity etiology includes a combination of excess dietary calories and decreased physical activity, coupled with either predisposing genetic factors or metabolic disorders such as insulin resistance. Adipose tissue secretes several metabolically important proteins known as 'adipokines' that play a major role in obesity and insulin resistance. High levels of a newly identified group of adipokines, called prokineticins, have been found in obese adipose tissues. Prokineticins are peptide hormones released principally from macrophages and reproductive organs. They act on the G protein-coupled receptors PKR1 and PKR2. This review aims to provide an overview of current knowledge of the role of prokineticins and their receptors in the development of obesity and insulin resistance.
Mots clés
Animals, Anti-Obesity Agents, therapeutic use, Appetite Depressants, therapeutic use, Eating, drug effects, Humans, Insulin Resistance, Obesity, prevention & control, Receptors, G-Protein-Coupled, therapeutic use, Receptors, Peptide, therapeutic use
Référence
Curr Opin Endocrinol Diabetes Obes. 2015 10;22(5):367-73